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Discovering the genetic changes underlying species differences is
a central goal in evolutionary genetics. However, hybrid crosses
between species in mammals often suffer from hybrid sterility,
greatly complicating genetic mapping of trait variation across species.
Here, we describe a simple, robust, and transgene-free technique to
generate “in vitro crosses” in hybrid mouse embryonic stem (ES) cells
by inducing random mitotic cross-overs with the drug ML216, which
inhibits the DNA helicase Bloom syndrome (BLM). Starting with an
interspecific F1 hybrid ES cell line between theMus musculus labora-
tory mouse and Mus spretus (∼1.5 million years of divergence), we
mapped the genetic basis of drug resistance to the antimetabolite
tioguanine to a single region containing hypoxanthine–guanine
phosphoribosyltransferase (Hprt) in as few as 21 d through “flow
mapping” by coupling in vitro crosses with fluorescence-activated cell
sorting (FACS). We also show how our platform can enable direct
study of developmental variation by rederiving embryos with contri-
bution from the recombinant ES cell lines. We demonstrate how
in vitro crosses can overcome major bottlenecks in mouse complex
trait genetics and address fundamental questions in evolutionary bi-
ology that are otherwise intractable through traditional breeding due
to high cost, small litter sizes, and/or hybrid sterility. In doing so, we
describe an experimental platform toward studying evolutionary sys-
tems biology inmouse and potentially in human and other mammals,
including cross-species hybrids.
interspecific hybrids | mitotic recombination | QTL mapping | genetics |
evolution
Discovering the genetic changes underlying the phenotypicdifferences between species is a central goal in evolutionary
genetics (1). However, hybrid crosses between even recently di-
verged species in animals often suffer from hybrid sterility (1, 2),
greatly complicating genetic mapping of trait variation, especially
in mammals. On the other hand, within-species genetic mapping
has been tremendously successful in linking genetic polymor-
phisms to trait variations in innumerable organisms since the
early 20th century (3–5). Genetic mapping typically involves
breeding and analyzing mapping panels to identify genetic loci
controlling trait variations, or quantitative trait loci (QTL). The
ability to disentangle linked genetic associations determines
mapping resolution and mainly depends on the number of mei-
otic cross-overs. Accordingly, researchers are driven to create
ever-larger mapping populations and/or accumulating recombi-
nation over at least two, often many generations to achieve gene-
level mapping resolutions (6–8). In the mouse, genetic studies
are complicated by the relatively long generation times and
small litter sizes, which often decline with increased inbreeding.
Consequently, compared with other classical model organisms
like yeast, worms, and Arabidopsis, genetic mapping in the mouse
requires far greater resources (6–8), such that relatively few
traits have been mapped to the gene level (but see landmark
studies identifying Tlr4 and Prdm9) (9, 10). This challenge was
particularly acute for crosses at or beyond the species level,
where hybrid sterility often makes it impossible to generate a
panel (if hybrids are viable in the first place). Nonetheless, the
potential to reveal unique biology occurring at the species
boundaries in mammalian evolution makes such panels worthy
attempts (11–15), even allowing for lower mapping resolu-
tion. This is because evolutionary changes in trait architec-
ture (including at the cellular or tissue level) can reveal much
about the underlying evolutionary process. Should genetic
exchange in hybrid animal genomes become feasible, direct
genetic mapping of species differences would become routinely
possible.
Significance
How species differ from each other is a key question in biology.
However, genetic mapping between species often fails because
of sterile hybrid crosses. Here, we have developed a technique
called in vitro recombination to circumvent breeding. We induced
genetic reshuffling through mitotic recombination with the drug
ML216 and mapped trait variations in a dish. Starting with hybrid
embryonic stem cells between the Mus musculus laboratory
mouse and Mus spretus spanning ∼1.5 million years of di-
vergence, we show that it is possible to map the gene responsible
for differential resistance to the drug tioguanine in as few as
21 days. Our technique opens up experimental avenues in genetic
mapping of various traits and diseases across mouse species.
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We set out to establish a universal method that allows genetic
mapping in mammals without breeding, even across divergent
species with viable but otherwise sterile hybrids. We opted to use
mouse embryonic stem (ES) cells to take advantage of the full
spectrum of genetic manipulations available in tissue culture. A
minimal system will have the two following features: an ability to
induce on-demand extensive genetic exchange; and genetic (and
trait) variation such as those found in F1 hybrid ES cells, ideally
between species.
Intriguingly, the technique to create genetic variation through
recombination has been in broad use in the mouse genetics
community, albeit never explicitly in F1 hybrid ES cells with the
goal of genetic mapping. In 2004, two independent groups
showed that recessive, biallelic mutants could be reliably re-
covered in mouse ES cells without breeding by suppressing the
DNA helicase Bloom syndrome (Blm; Fig. 1A) (16, 17). Yusa
and coworkers (18) showed that these recessive phenotypes were
revealed through mitotic recombination between homologous
chromosomes. We reasoned that the same mechanism could be
leveraged to generate genome-wide random mitotic recombina-
tion. This mechanism enabled the creation of panels of arbitrary
size carrying recombinant genomes, while avoiding the limita-
tions of hybrid sterility or inbreeding depression (Fig. 1B).
Results
To test if BLM inhibition could lead to elevated homologous
recombination rates in mitosis, we inhibited BLM in a number of
mouse ES cell lines using a recently discovered small-molecule
inhibitor, ML216 (Fig. 1C) (19). As a first test, we started with
F1 ES cells between the laboratory mouse strains C57BL/6J
(“BL6” in short) and 129 that carried a targeted transgene as a
hemizygous allele at the ROSA26 locus on distal chromosome 6.
We estimated homologous recombination by counting colony
survival under fialuridine (FIAU) treatment, which selected
against the transgene consisting of hygromycin phospho-
transferase–thymidine kinase (HyTK) and a green fluorescent
protein (GFP; Fig. S1). We found that BLM inhibition led to
highly elevated rates of homologous recombination, as revealed
by increased numbers of FIAU-resistant colonies [Fig. 1C;
in vitro recombination (IVR) rate: 2.9 × 10−4 per cell per gen-
eration] and the appearance of mosaic GFP expression within a
colony (Fig. 2 A, Right). This is consistent with reported rates
under Blm suppression or disruption (targeted tetracycline in-
hibition or knockout alleles: 2.3 × 10−4 to 4.2 × 10−4 vs. wild-type
rates between 8.5 × 10−6 and 2.3 × 10−5) (16, 17). The small-
molecule BLM inhibitor ML216 offers unique experimental
advantages, because its application is simple, rapid, and re-
versible, eliminating the use of transgenes against Blm (16, 17) or
repeated transfections of small interfering RNA to achieve
continued suppression of Blm. Importantly, elevated homolo-
gous recombination under BLM inhibition was not associated
with increased aneuploidy (n = 154 metaphase spreads; Mann–
Whitney U test, W = 1,871, h1 > 0, nonsignificant; Fig. S2A).
Furthermore, ML216-treated ES cells retained robust expression
of NANOG, a key stemness marker (Fig. S3B).
To determine the frequency and distribution of mitotic cross-
overs under ML216-mediated BLM inhibition, we sequenced
and compared the genomes of 11 clones that survived ganciclovir
selection (a FIAU alternative; Fig. 2B). We found that the
transgene had been lost in all sequenced clones (n = 11 of 11 vs.
9 of 826; Fisher exact test, P < 2.2 × 10−16). Instead, large
chromosome segments had undergone mitotic cross-over, re-
moving the transgene in the process. Notably, cross-over break-
points were recovered not at the transgene itself, but up to many
megabases away (all 11 cross-overs were centromeric to chro-
mosome 6; 113 Mbp; Fig. 2B; note that shared breakpoints here
may correspond to related clones). This was consistent with the
negative selection, because chromosome segments telomeric to
the cassette should have no effect on selection. We also treated
the F1 hybrid ES cell line (BL6 × CAST) F1 (20) derived from
BL6 and Mus castaneus (CAST/EiJ, abbreviated to CAST; di-
verged ∼0.5 million years ago, or 7.9 SNPs per kbp; compare 1.7
SNPs per kbp between BL6 and 129) with ML216 but otherwise
grown without selection. We screened 136 randomly picked
ML216-treated clones for loss of heterozygosity (LOH) re-
combinants and recovered recombinants in both BL6/BL6 and
CAST/CAST directions on chromosome 1. Sequencing of rep-
resentative clones revealed conversion from F1 heterozygous
genotypes toward both homozygous genotypes at the telomeres
(Fig. 2C, clones 21 and 50; note also additional recombination on
chromosome 13). In contrast, control nonrecombinant clones
retained heterozygosity at the telomeres (clones 54 and 56).
However, even here we discovered a single clone carrying ad-
ditional internal recombinants on chromosome 1 (Fig. 2C). In
both experiments, we noted that cross-overs created by mitotic
recombination usually occurred only on one or few chromo-
somes at a time (Fig. 2 B and C and Fig. S4) (18, 21), unlike
in meiosis with typically one cross-over per chromosome arm.
Together, the data show that BLM inhibition efficiently gener-
ated IVR across wide evolutionary distance, and IVR ES cell
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Fig. 1. IVR via Blm helicase suppression. (A) Blm encodes a helicase normally
active during mitosis. Loss of Blm activity leads to increased improper sister
chromatid exchange as well as recombination between homologous chro-
mosomes. Mitotic recombination can give rise to recombinant diploid
daughter cells with LOH between the breakpoint and the telomeres. (B) IVR
allowed the circumvention of hybrid sterility in crosses between the labo-
ratory mouse, e.g., BL6, and a murine sister species SPRET. (BL6 × SPRET)
F1 hybrid mice were viable and allowed derivation of F1 ES cells despite male
sterility (25). Applying IVR to F1 ES cells allowed rapid and efficient gener-
ation of recombinant ES cell panels for genetic mapping. (Scale bar: 50 μm.)
chr, chromosome. (C) Efficiency of IVR was estimated by colony survival as-
say. We estimated the recombination rate between homologous chromo-
somes with cells hemizygous for a dominant selectable marker (HyTK;
green). We induced IVR by adding a small-molecule BLM inhibitor, ML216
(19), to the culturing medium for 1 or 5 d. Under FIAU negative selection,
cells having undergone mitotic recombination to become homozygous for
the wild-type BL6 alleles (blue) survived, while nonrecombined cells or
recombinant cells retaining the HyTK transgene metabolized FIAU, resulting
in cell death due to misincorporation of toxic nucleotide analogs (top and
middle cells with red chromosomes). Under ML216 treatment (25 μM), IVR
rate was estimated to be 2.9 × 10−4 per cell per generation, yielding 800–
1,500 FIAU-resistant colonies per million following treatment.
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panels may constitute genetically distinct lineages suitable for
genetic mapping.
Our experiments to determine IVR rate demonstrated that
the collective location of recombination breakpoints could reveal
the position of the selectable transgene (HyTK or GFP), but
under mitotic recombination, the critical interval was defined
primarily on the centromeric side due to telomeric LOH. To
further illustrate the potential of this approach, we used IVR to
map naturally occurring variations. One classical polymorphism
is the 25- to 75-fold increased activity of the Mus spretus “a”
allele of hypoxanthine–guanine phosphoribosyltransferase (Hprta)
compared with the laboratory mouse Hprtb allele (22). Impor-
tantly, HPRT metabolizes the antimetabolite tioguanine (6-TG)
and causes cytotoxicity. It should be noted that, besides the
known Hprt allozyme polymorphism, 6-TG susceptibility itself
has not been mapped genetically within or between mouse spe-
cies. Here, we expected ES cells carrying Hprta to be highly
susceptible to 6-TG treatment, whereas Hprtb/b or Hprt−/− ES
cells should survive far higher 6-TG concentrations (Fig. S5). We
set out to map the QTL for differential 6-TG susceptibility using
a bulk segregant assay simply by comparing allele frequencies
across the genome between pools of 6-TG–susceptible and
–resistant ES cells.
We first confirmed the absence of chromosome-scale rear-
rangements between the parental strains that could preclude
mapping using the de novo assembled genomes of the parental
strains made available by the Wellcome Trust Sanger Institute
(BL6 and SPRET/EiJ, abbreviated to SPRET here; ∼1.5 million
years of divergence or 16.0 SNPs per kbp) (23, 24). We gener-
ated IVR panels by treating a female (BL6 × SPRET)F1 hybrid
ES cell line (“S18”) (25) with ML216 over 5, 10, and 21 d (Fig.
3A). The use of a female ES cell line, which carried two active X
chromosomes before the onset of X inactivation during differ-
entiation (26), allowed direct selection on the alternative Hprta
and Hprtb alleles. After confirming biallelic Hprt expression in
S18 cells using quantitative PCR, we treated control and IVR
S18 cells with 6-TG and determined cell viability via a 4′,6-
diamidino-2-phenylindole (DAPI) exclusion assay. Damaged
cells with ruptured membrane exhibited rapid uptake of DAPI, a
feature unaffected by ML216 treatment, and were distinguish-
able by fluorescence-activated cell sorting (FACS; “live” pro-
portions under ML216 treatment vs. live proportions under 6-
TG treatment, n = 5 paired treatments; Kruskal–Wallis test, χ2 =
13.17, df = 1, P < 0.0003; Fig. 3A and Fig. S6). We separately
recovered and sequenced each “resistant” (6-TGR) and “sus-
ceptible” (6-TGS) pool (Fig. 3A). Under both 5- and 21-d
ML216 treatment, a large skew toward excess SPRET coverage
was observed on chromosome X in the 6-TGS relative to the 6-
TGR pool (Fig. 3 A and B; differential SPRET bias as a fraction
of all reads in adjacent megabase windows between the two
pools, with raw SPRET bias ranging from 1 for SPRET-only to −1
for BL6-only). This was in stark contrast to the genomic back-
ground, which showed little bias for either SPRET or
BL6 contributions (Fig. 3 A and B, also Fig. S6A). The region
with the greatest SPRET bias was found on chromosome X near
Hprt (Fig. 3C; common region found in both 5- and 21-d
ML216 treatments between 49 and 80 Mbp; also see chromo-
some X in Fig. S6A and discussion in SI Text). Here, our forward
genetic mapping for 6-TG susceptibility clearly identified a single
locus, suggesting that 6-TG susceptibility depended only on Hprt
genotypes. To confirm the role of Hprt in mediating differential
6-TG susceptibility beyond bulk sequencing, we also sequenced
46 individual 6-TGR IVR clones after 10-d ML216 treatment to
determine their recombination breakpoints (Fig. 3C). Echoing
the skewed cross-over patterns centromeric to the HyTK selec-
tion cassette (Fig. 2B), we observed more SPRET-to-BL6 than
BL6-to-SPRET centromeric recombinants (n = 35 vs. 8, P ≤ 2 ×
10−5, exact binomial test, h1 ≥ h0) and also ruled out aneuploidy
or deletion ofHprta as major contributors to 6-TG resistance. We
note, however, that despite the strongly skewed ratio of 27 BL6/
BL6 homozygous clones at the Hprt locus, of 46 total recovered
clones, we still observed 9 heterozygotes and 10 SPRET/SPRET
homozygous clones (BL6/BL6 at the Hprt locus: 58.6%; χ2 test
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Fig. 2. Widespread IVR across a range of evolutionary divergence. (A) Se-
lection cassette transgene (HyTK-GFP-Neo). ES cell colonies displayed mosaic
GFP expression within a colony when cultured with ML216, but not under
control conditions, consistent with homologous recombination and loss of
GFP through IVR. Recombination between homologous chromosomes could
result in daughter cells with two wild-type (BL6 allele; dark) or transgenic
copies (129 allele; bright). Early recombination events followed by random
cell loss during clonal expansion could produce completely dark colonies.
(Scale bars: 100 μm.) (B) Double-selected clones. After expansion under
negative selection against the transgene (both ganciclovir and FIAU kill cells
expressing HyTK), 11 ganciclovir-resistant and GFP-negative colonies were
whole-genome sequenced. Selection favored loss of transgene (homozygous
BL6/BL6 genotypes) at distal chromosome 6. In contrast to normal meiotic
recombination (averaging one or more cross-overs per chromosome pair),
mitotic recombination typically affected only a single chromosome pair:
Much of the genome remained heterozygous (Het.; yellow), with the ex-
ception of the transgene-carrying chromosome 6 (mostly BL6/BL6; blue), the
single 129 chromosome X (male; 129; red), and at tips of certain chromo-
somes (e.g., chromosomes 1 and 12). Mitotic recombination events con-
verted genotypes telomeric to the breakpoint toward homozygosity (LOH;
yellow to blue). Cen, centromere; n.d., not determined; Tel, telomere. (C)
Spontaneous recombination. IVR also occurred in cells carrying divergent
genomes with no transgenes. (BL6 × CAST) F1 hybrid ES cells were treated
with ML216 and screened by PCR genotyping at diagnostic telomeric
markers. Selected clones (two recombinant and control clones each) were
whole-genome sequenced, showing recombination events toward both
homozygous genotypes, consistent with PCR genotype screening results
(total breakpoints per clone ranged from zero to two). Additional re-
combination events were also recovered, even though the chromosome
1 telomeric marker remained heterozygous (clone 54). These clones also
carried nonrecombined chromosomes (e.g., chromosome 6; fully heterozy-
gous; yellow).
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using observed allele counts, χ2 = 13.17, df = 2, P ≤ 0.002). Close
examination of our flow cytometry data suggests that the original
DAPI-only FACS gating may not have been sufficiently exclusive
(as opposed to gating using additional channels; Fig. 3A and Fig.
S5, Right). Other alternative explanations may be a quantitative,
rather than absolute allelic difference in susceptibility to 25 μM
6-TG treatment (Fig. S5) or other mutation(s) at Hprt or else-
where leading to 6-TG resistance. We concluded that we were
able to perform forward genetic mapping using IVR and recover
a single region containing Hprt as the most likely gene underlying
6-TG susceptibility differences between BL6 and SPRET.
The ability to easily circumvent hybrid sterility in evolution-
arily divergent murine species led us to ask what developmental
phenotypes may arise from such otherwise inaccessible genetic
configurations (M. spretus—laboratory mouse hybrid males are
sterile, following Haldane’s rule; back-crosses using female hy-
brids are possible but extremely challenging) (15). Assaying de-
velopmental phenotypes from evolutionarily divergent hybrid ES
cells is nontrivial, because hybrid sterility makes conventional
rederivation impossible due to a block in germ-line transmission
in the chimera generation. Instead, we directly produced em-
bryos via laser-assisted morula injection, a technique widely used
for direct phenotyping of fully ES cell-derived founder mice (27),
using two karyotypically normal but genetically distinct IVR ES
cell lines along with control, nonrecombined S18 cells (IVR
1 and 2; Figs. S2 and S7 and Movies S1–S3). We succeeded in
obtaining multiple embryos per line at embryonic day (E) 14.5 of
development (n = 36; 24 from IVR lines vs. n = 9 untreated
S18 line). Using high-resolution microcomputer tomography
(microCT), we observed that the embryos from the untreated
clones showed uniformly normal development, whereas embryos
from both IVR lines showed both normal development and
dramatic craniofacial and neural tube closure defects (two ab-
normal embryos of four scanned embryos in IVR line 1; two of
seven in line 2; and zero of six from the original S18 line; Fig. 4,
Fig. S8, and Movies S1–S3). Neural tube and craniofacial defects
are among the most common developmental defects due to the
complex coordination of cell migration and cell–cell communi-
cations, which may be impaired due to novel genetic combina-
tions in the IVR lines, or incompatibility between the host and
ES cell-derived cells in a chimera (Fig. S7). Besides major de-
velopmental defects, we also made 3D measurements from
various organs, including subregions of the brain, heart, and
liver, in individual embryos from each ES cell line (Fig. S8). This
approach illustrated the feasibility of generating recombinant
mice from sterile mouse crosses, which may make it possible to
map the genetic basis of evolutionary developmental variation
between species.
Discussion
A central goal of evolutionary genetics is to identify how muta-
tions arose during evolution and influenced phenotypes. For
many organisms, a major barrier has been the inability to reliably
generate diverse and large mapping panels of sufficient evolu-
tionary diversity. Here, we describe a simple and robust method
to make “in vitro crosses,” resulting in panels with inter-cross-
like homozygous genotypes from otherwise sterile interspecific
hybrid crosses. Being able to bring forth genetic diversity in a
Petri dish creates the unique opportunity to conduct mouse ge-
netic mapping at unprecedented speeds with “flow mapping”
[similar to “X-QTL” in yeast (28)] or arbitrarily large panels
unmatched by most other model organisms, except possibly yeast
(21, 28). As renewable stem cells, IVR panels can be expanded,
archived, and shared, offering a cellular resource with many of
the advantages sought from traditional community resources
such as recombinant inbred (RI) line panels. Furthermore, we
have shown that our IVR method works in a broad range of ES
cells. With millions of potentially recombinant (thus genetically
distinct) ES cells in a Petri dish, we demonstrated how IVR
enabled mapping of QTLs for drug resistance in as few as 6 d
(with an estimated total of five doublings over 5 d). Putting this
in context, such an experiment using traditional mouse crosses
would have taken 450 d, based on the typical mouse generation
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Fig. 3. In vitro genetic mapping of variation in 6-TG susceptibility between
divergent species. (A) A female ES cell line S18 derived from aM. spretus and
BL6 F1 interspecific hybrid was treated with ML216 (25 μM) and subjected to
the antimetabolite 6-TG for 1 d before FACS. ES cells were evaluated for
viability based on DAPI exclusion. Resistant and susceptible (6-TGR and -TGS)
subpopulations were gated conservatively (shaded arrows) and pooled for
sequencing. Individual clones from the 10-d ML216 treatment were cultured
and whole-genome sequenced. (B) An excess of SPRET contribution on
chromosome X between the 6-TGR and -TGS pools suggested that a single
locus conferred 6-TG susceptibility. Allele counts were shown as the differ-
ence in SPRET bias between the 6-TGs and the 6-TGR samples (as an internal
ML216 treatment control) after 5-d (brown) and 21-d (red) ML216 treatment
(mean differential SPRET bias ± SEM in megabase windows). In both cases,
the genome-wide peak window contains the Hprt gene with the SPRET allele
showing significantly increased susceptibility. (C) Detailed view of chromo-
some X, showing differential SPRET bias for the 5-d (brown) and 21-d (red)
ML216 treatment as described above. In addition, 6-TGR clones following 10-
d ML216 treatment were sequenced to determine recombination break-
points. In contrast to the differential bias toward SPRET observed in the
susceptible 5- and 21-dML216 samples, the raw SPRET bias in the solitary 6-TG–
resistant sample showed an opposite skew toward BL6 in the 10-d ML216-
treatment (blue). Regions deviating from 0 (thus showing bias) after local
smoothing in each sample are shown as bars with mark showing maximum
skew. Together, they define a common region (shaded) on chromosome X
containing Hprt. Cross-overs in individual 6-TGR clones (10-d ML216 treat-
ment) recombined significantly more likely in the SPRET-to-BL6 direction
(S > B = 37; B > S = 5; P ≤ 2 × 10−5) between the centromere (Cen) and
Hprt, consistent with strong selection favoring the BL6 Hprtb allele. In
contrast, only three additional cross-overs were detected telomeric to
Hprt. Tel, telomere.
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time of 90 d, assuming that hybrid sterility could be overcome
and allowing for selfing.
We see IVR as a complementary extension to classical or-
ganismal genetic mapping panels. In the mouse, the largest or-
ganismal RI panel BXD contains ∼160 lines (with most
published work based on the ∼35 original BXD strains) (29), and
attempts in generating panels incorporating greater divergences
encountered enormous challenges (30). Nevertheless, mouse RI
resources represented some of the most powerful tools available
to dissect system genetics in the mouse, the prime biomedical
model organism (31). Seen in this light, IVR represents an al-
ternative approach that could greatly extend the available re-
newable resources, not least because the genotype combinations
between divergent species are hitherto impossible to obtain in
the first place.
Recently, Sadhu et al. (21) also achieved a major advance in
genetic mapping using CRISPR/Cas9-mediated mitotic recombi-
nation in yeast. In contrast to CRISPR targeting, our transgene-
free approach offers the simplicity of inducing genome-wide
recombinants by the simple addition of a single inexpensive
small molecule to the tissue culture medium. Going forward, we
envision a combined, complementary approach to IVR: using
BLM inhibition for mapping panel generations and efficient QTL
identification, then switching to targeted transgene-based screen-
ing or CRISPR/Cas9-based IVR for fine-scale mapping.
In addition to the traits we have investigated, M. spretus and
theMus musculus laboratory mouse differ in a number of distinct
traits, such as longevity and telomere lengths (32), cancer and
inflammation resistance (33, 34), and metabolism (35). Many of
these traits have tissue or cellular models suitable for IVR
mapping panels or flow mapping through fluorescent detection
of specific proteins or metabolites. Future experiments may also
probe even greater evolutionary divergence: Early work has
shown that F1 hybrids spanning as much as 6 million years be-
tween M. musculus and Mus caroli was viable (36). Given active
development in single-cell genomics and disease modeling from
patient-specific induced pluripotent stem cells, including orga-
noids or organ-on-a-chip microfluidics systems, we anticipate
that the in vitro recombinant platform can be broadly applied to
accelerate the identification of the genetic basis of many traits
and diseases.
Materials and Methods
Animal Care and Use. All animal experiments have been approved by the
applicable animal welfare ethics committees: Faculty of Sciences, Ghent
University (reference no. 06/022); and Landesdirektion Sachsen, Germany,
permit 24-9168.11-9/2012-5.
Cell Culture. Unless otherwise stated, ES cell lines were cultured on SNL76/7-
4 feeder cells in attachment factor (AF)-coated plates under 2i medium,
supplemented with leukemia inhibitory factor (LIF) (see SI Methods
for details).
BLM Inhibition Using ML216. BLM inhibition was performed by using 25 μM
ML216 (Sigma-Aldrich) in 2i/LIF medium on inactivated feeders.
Generation of HyTK-EGFP-Neo Cell Line. Starting with G4 ROSALUC B12 ES cells
(37), we replaced the cassette at the ROSA26 locus with a cassette carrying
two selectable markers, HyTK and enhanced GFP (EGFP; selectable in
fluorescence-assisted cell sorting; Fig. S1; see SI Methods for details). Suc-
cessful replacement of the cassette was confirmed through selection by us-
ing geneticin (G148; ThermoFisher Scientific) and genotyping.
Colony Survival Assay. HyTK-EGFP-Neo cells were seeded at a density of 5 ×
105 per 10 cm AF per feeder plate, followed by 25 μM ML216 treatment for
1 or 5 d. Before the start of negative selection, cells were replated at 2 × 105
per 10 cm AF per feeder plate, and FIAU (0.2 μM; Sigma-Aldrich) or ganci-
clovir (10 μM; Sigma-Aldrich) selection was applied for 5 d. Colonies were
stained with the alkaline phosphatase kit (EMD Millipore), photographed,
and counted to determine survival rates. The entire procedure was repeated
multiple times, and the survival colony counts were averaged to determine
IVR rate.
Screening for Spontaneous Recombinant ES Cell Colonies. Cells were treated
with ML216 for 2 d at a concentration of 5 μM and then for 3 d at a con-
centration of 25 μM. Cells were then replated and cultured for 5 d in 2i/LIF
without ML216. A total of 189 colonies were randomly picked (without se-
lection), of which 136 were screened with multiplexed genotyping.
Multiplexed Genotyping for Detection of LOH. Diagnostic markers between
BL6, CAST, and SPRET strains at tips of each chromosome were designed to
track the presence of each allele. The markers were amplified with
fluorescence-tagged primers as proposed in ref. 38 (see SI Methods and
Table S1 for details). The PCRs were pooled at equimolar proportions and
analyzed with a 3730xl DNA Analyzer capillary sequencer (ThermoFisher
Scientific) and scored for conversion from heterozygous into homozygous
genotypes (LOH) at the tips of each chromosome.
The 6-TG Treatment and DAPI Exclusion Assay. Before the main experiments,
killing curves for 6-TG (Sigma-Aldrich) was performed by using a WST-1 assay
(Roche) according to the manufacturer’s instructions (Figs. S3A and S5, Left).
For the main experiments, the S18 ES cell line was cultured for 5, 10, or 21 d
with 25 μM ML216. Following the designated ML216 treatment, the cells
were replated and treated with 25 μM 6-TG in 2i/LIF. We determined “live/
dead” cell viability by using DAPI staining (1 μg/mL; Sigma-Aldrich) after 1 d
of 25 μM 6-TG treatment.
FACS. Flow cytometry was performed by using an Aria II Cell Sorter (Becton
Dickinson GmbH). We defined the 6-TGR and -TGS populations by using the
DAPI exclusion assay in reference ES cell populations. In sorting experiments,
ML216-treated or control 6-TGR and -TGS population were recovered for
sequencing. For quantification, we performed post hoc analysis using the R
Bioconductor package flowCore (39), principally by clustering using the
forward scatter area and DAPI/Pacific Blue-A channels into live and dead
clusters using mclust (Version 5.2) (40, 41) in 6-TG–treated experiments,
considering ML216-treated and controls separately (Fig. S5).
Sequencing and Analysis Pipeline. Sequencing libraries for high-throughput
sequencing were generated by using the Nextera DNA Library Prep Kit
(Illumina, Inc.) according to manufacturer’s recommendations or equivalent
purified Tn5 transposase as described in ref. 42. Each sample (FACS-sorted
clones, single colonies or pooled cells) was barcoded through PCR extension
by using an i7-index primer (N701–N763) and the N501 i5-index primer.
Pooled libraries were sequenced by a HiSeq 3000 (Illumina) and analyzed by
using a custom pipeline (see SI Methods for details). We performed geno-
typing based on allelic coverage per megabase using known informative
A B C
Fig. 4. Accessing developmental phenotypes in recombinants between
evolutionarily divergent species. Embryos at midgestation (14.5 d after
fertilization) were derived from nonrecombinant F1 S18 ES cells (A) and
IVR lines 1 (B) and 2 (C; see Methods for details). Embryos were dissected,
contrast-stained, and scanned by using X-ray microCT at 9.4-μm resolution.
The high scanning resolution allowed identification and precise mea-
surements of individual organs (colorized here). Major developmental
craniofacial and neural tube closure defects were observed in the IVR lines
(B; caudal view with arrowhead indicates neural tube lesion). (Scale bars:
200 μm.)
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variants between the BL6, CAST, and SPRET strains (Mouse Genomes Project
Version 3 dbSNP Version 137 release) (24). Scripts are available at: https://
github.com/evolgenomics/HybridMiX.
Laser-Assisted Morula Injection. ES cell-derived embryos were obtained
through injection into eight-cell-stage embryos (morulae) as described in ref.
27. The introduction of excess ES cells was expected to lead to embryos with
fully ES cell contributions. At 14 d after the injection and subsequent embryo
transfer into surrogates (approximating developmental stage E14.5), the
gestation was terminated, and embryos were dissected and fixed with 4%
paraformaldehyde for microCT scanning. Due to sample preparation, gen-
otyping of scanned embryos was not performed. Instead, control (unscan-
ned) embryos were dissociated and genotyped at diagnostic loci, confirming
ES cell contributions from the respective cell lines.
microCT. Soft-tissue X-ray contrast staining was done via 4-d perfusion in 25%
Lugol’s or iodine potassium iodide solution. Then the embryos were rehy-
drated, mounted in 1% low-melting agarose, and scanned with a Skyscan
1173 instrument (Bruker Corporation) at 9.96-μm resolution (0.5-mm alu-
minum filter, energy at 70 kV and 110 μA). Image analysis, segmentation,
and visualizations were performed by using Amira (Version 6.2.0; FEI) with
the XImagePAQ extension 6.2.
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